Piero Ruscitti 1 , Paola Cipriani 1 , Vasiliky Liakouli 1 , Francesco Carubbi 1 , Onorina Berardicurti 1 , Paola Di Benedetto 1 , Francesco Ciccia 2 , Giuliana Guggino 2 , Saverio Alvaro 1 , Giovanni Triolo 2 , Roberto Giacomelli 1 Show Affiliations »
Abstract
BACKGROUND: Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients. OBJECTIVE: We reviewed the role of IL-1β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. METHOD: After literature search, the available evidence has been selected and commented in the text. RESULTS: During RA, it is well known that different inflammatory cytokines, such as interleukin-1β (IL-1β), are pivotal pathogenic mediators and their role has been largely confirmed in clinical settings. Similarly, it has been shown that the excess of nutrients, secondary to over-nutrition, may activate the immune system, leading to an increased production of inflammatory cytokines, including IL-1β, suggesting new possible therapeutic targets. CONCLUSION: Although further studies are needed to fully investigate the pathogenic interplay between inflammation and metabolic disorders, IL-1β has been implicated in both RA and T2D pathogenic mechanisms. Intriguingly, the potential role of anti-IL-1 drugs has been proposed in RA patients affected by T2D. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
BACKGROUND: Although in the past, prevention of the joint destruction and disability was strongly emphasised in Rheumatoid Arthritis (RA ), at present, a growing body of evidence is focused at identifying the best management of associated comorbidities, such as Type 2 Diabetes (T2D). Recently, the hypothesis that blocking pro-inflammatory activity may be helpful in the treatment of some comorbidities has been proposed in RA patients . OBJECTIVE: We reviewed the role of IL-1 β during RA and T2D, the efficacy of IL-1 blocking agents in controlling both diseases and, possible, decreasing the concomitant enhanced atherosclerotic process. METHOD: After literature search, the available evidence has been selected and commented in the text. RESULTS: During RA , it is well known that different inflammatory cytokines, such as interleukin-1β (IL-1 β), are pivotal pathogenic mediators and their role has been largely confirmed in clinical settings. Similarly, it has been shown that the excess of nutrients, secondary to over-nutrition, may activate the immune system, leading to an increased production of inflammatory cytokines, including IL-1 β, suggesting new possible therapeutic targets. CONCLUSION: Although further studies are needed to fully investigate the pathogenic interplay between inflammation and metabolic disorders , IL-1 β has been implicated in both RA and T2D pathogenic mechanisms. Intriguingly, the potential role of anti-IL-1 drugs has been proposed in RA patients affected by T2D. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.
Entities: Disease
Gene
Species
Keywords:
Anakinra; IL-1β; cardiovascular risk; diabetes; pathogenesis; rheumatoid arthritis; therapy.
Mesh： See more »
Substances： See more »
Year: 2018
PMID： 29542422 DOI： 10.2174/1574887113666180314102651
Source DB: PubMed Journal: Rev Recent Clin Trials ISSN： 1574-8871